Key trends include strategic CDMO partnerships and a shift to in vivo administration, enhancing accessibility and innovation ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes.

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are common-sense reforms that will address the unique characteristics of cell and ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, today announced the ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, and Genetix Biotherapeutics Inc., a ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...

Raw materials play a critical role in cell therapy manufacturing. Choosing suboptimal materials at any stage of development ...

Discover how platformed lentiviral manufacturing and ready-to-deploy CAR-T solutions are breaking the critical barriers of ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a ...